Yüklüyor......
PCI-32765, the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
Ibrutinib is a potent covalent kinase inhibitor that targets BTK. BTK, or Bruton’s tyrosine kinase, is an obvious target for therapy of B cell diseases because inactivating mutations lead to B cell aplasia in humans and the disease X-linked agammaglobulinemia. Ibrutinib has modest cytotoxicity again...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3584329/ https://ncbi.nlm.nih.gov/pubmed/23296407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11899-012-0147-9 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|